Big Chemical Encyclopedia

Chemical substances, components, reactions, process design ...

Articles Figures Tables About

Doxorubicin, drug-polymer conjugate

Vasey, P. A., Kaye, S. B., Morrison, R., et al. Phase I clinical and pharmacokinetic study of PK1 [lV-(2-hydroxypropyl)methacrylamide copolymer doxorubicin] First member of a new class of chemotherapeutic agents-drug-polymer conjugates. Cancer Research Campaign Phase I/II Committee. Clin. Cancer Res. 5(l) 83-94. 1999. [Pg.370]

Vasey, P. Kaye, S.B. Morrison, R. Twelves, C. Wilson, P. Duncan, R. Thomson, A.H. Murray, L.S. Hilditch, T.E. Murray, T. Burtles, S. Fraier, D. Frigerio, E. Cassidy, J. Phase I clinical and pharmacokinetics study of PKl (iV-(2-hydroxy propy l)methacrylamide copolymer doxorubicin) first member of a new class of chemotherapeutic agents - drug-polymer conjugates. Chnical Cancer Research 1999, 5, 83-94. [Pg.1337]

The potentiating effects of polymers on drug accumulation in tumours have been previously reported for several polymer-based eompositions . This phenomenon, also known as Enhanced Permeability and Retention effect (EPR), was described for drug/polymer conjugates (PK-1, PEG-polyaspartate-doxorubicin) and some other supramolecular complexes, such as liposomes. Moreover, the ability to facilitate accumulation of various compounds in tumour tissues was specifically attributed to Pluronic copolymers. Therefore, it can be concluded that the increased drug level and residence time in tumour tissue observed in the SP1049C-treated group of animals are likely related to EPR effect. [Pg.133]

Fig. 14 A Polymer directed enzyme prodrug therapy (PDEPT) is a two-step approach that relies on activation of a polymer-drug conjugate by a complementary polymer-enzyme conjugate B PKl activated HPMA copolymer-Gly-Gly-cathepsin B C HPMA copolymer-Gly-Gly-cephalosporin-doxorubicin activated by HPMA copolymer-Gly-Gly-/3-lactamase D Etoposide prodrug (candidate for polymer conjugation) activated by HPMA copolymer-catalytic antibody 38C2... Fig. 14 A Polymer directed enzyme prodrug therapy (PDEPT) is a two-step approach that relies on activation of a polymer-drug conjugate by a complementary polymer-enzyme conjugate B PKl activated HPMA copolymer-Gly-Gly-cathepsin B C HPMA copolymer-Gly-Gly-cephalosporin-doxorubicin activated by HPMA copolymer-Gly-Gly-/3-lactamase D Etoposide prodrug (candidate for polymer conjugation) activated by HPMA copolymer-catalytic antibody 38C2...
Veronese FM, Schiavon O, Pasut G, Mendichi R, Andersson L, Tsirk A, Ford J, Wu G, Kneller S, Davies J, Duncan R (2005) PEG-doxorubicin conjugates influence of polymer structure on drug release, in vitro cytotoxicity, biodistribution, and antitumor activity. Bioconjug Chem 16 775-784... [Pg.137]

Of the non-antibody, non-liposome based drug targeting strategies, most of the (limited) clinical experience has been obtained with polymer-based conjugates of anticancer drugs. The most widely employed drugs for this application are cytotoxic agents such as doxorubicin and... [Pg.14]

See other pages where Doxorubicin, drug-polymer conjugate is mentioned: [Pg.86]    [Pg.208]    [Pg.1153]    [Pg.351]    [Pg.3887]    [Pg.103]    [Pg.3886]    [Pg.223]    [Pg.338]    [Pg.392]    [Pg.17]    [Pg.37]    [Pg.45]    [Pg.71]    [Pg.46]    [Pg.119]    [Pg.234]    [Pg.128]    [Pg.11]    [Pg.46]    [Pg.119]    [Pg.132]    [Pg.133]    [Pg.302]    [Pg.182]    [Pg.10]    [Pg.178]    [Pg.245]    [Pg.1462]    [Pg.121]    [Pg.645]    [Pg.112]    [Pg.117]   
See also in sourсe #XX -- [ Pg.254 , Pg.255 ]



SEARCH



Doxorubicin

Doxorubicin conjugate

Doxorubicine

Drug conjugates

Drug conjugation

Polymer drugs

Polymer-drug conjugate

© 2024 chempedia.info